Introduction {#Sec1}
============

Adiponectin, a major adipokine secreted by adipose tissue^[@CR1]^, has attracted much attention due to its anti-inflammatory and insulin-sensitizing properties as well as its beneficial role in glucose metabolism^[@CR2]^. Animal studies and experimental studies have shown that adiponectin improves insulin sensitivity^[@CR3],[@CR4]^, thus may prevent the development of type 2 diabetes (T2D). A meta-analysis in year 2009 summarized data from 13 prospective studies in various populations, and confirmed an inverse association between adiponectin levels and T2D risk^[@CR5]^, since then, many more studies have been published with variability in the strength of the adiponectin-T2D association^[@CR6]--[@CR23]^. Most of the previous studies have been conducted in the Western populations, and a few were conducted among Asian populations such as Japanese, Indians and Koreans. Chinese have lower adiponectin levels compared to other ethnic groups^[@CR24]^. Meanwhile, Chinese are also particularly sensitive to the detrimental metabolic effects of greater body fatness^[@CR25]^. So far only a relatively small study (76 T2D cases) has examined the association between adiponectin levels (binary variable) and T2D risk in a Hong Kong Chinese population in the context of T2D prediction model^[@CR26]^. However, the shape of the association, and its potential confounders or modifying factors are unclear in a Chinese population.

The results from previous studies on the adiponectin-T2D relationship have not been entirely consistent. While some studies have reported a non-linear association^[@CR13],[@CR27]^, others have observed a linear relationship^[@CR5],[@CR21]^. Furthermore, data were conflicting on whether the association was modified by gender^[@CR10],[@CR13],[@CR15],[@CR17],[@CR28]--[@CR31]^ or levels of obesity^[@CR13],[@CR22],[@CR27],[@CR30],[@CR32]^, and whether adiponectin improved T2D prediction significantly^[@CR6],[@CR16],[@CR26],[@CR33]--[@CR37]^. Moreover, the last meta-analysis pooled risk estimates from models that did not adjust for metabolic variables such as lipids, markers of inflammation, glycaemia and insulin sensitivity^[@CR5]^.

In this context, we first conducted a case-control study nested within the prospective, population-based cohort, the Singapore Chinese Health Study (SCHS), to quantify the association between plasma adiponectin levels and risk of incident T2D in a Chinese population. We adjusted for blood lipids, inflammatory biomarker, glucose and insulin levels in the multivariable models to further test the potential mediation effect. We also assessed the incremental value of adiponectin in T2D risk prediction over established risk factors in this population. We further conducted an updated meta-analysis of published reports on circulating adiponectin and T2D, involving another 33 population-based longitudinal studies. We performed comprehensive stratified analysis to explore the heterogeneity among different subgroups and examined the dose-response relationship between adiponectin and T2D risk in the updated meta-analysis.

Results {#Sec2}
=======

Results in the SCHS {#Sec3}
-------------------

The process of selecting participants from SCHS in this study is presented in Supplemental Figure [S1](#MOESM1){ref-type="media"}. The baseline characteristics of cases and controls are shown in Table [1](#Tab1){ref-type="table"}. The mean age (standard deviation \[SD\]) of the participants was 59.7 (6.2) years and 58.7% were females. As expected, cases had high-risk profiles except for the matching factors, including higher body mass index (BMI) and higher prevalence of hypertension. No significant differences were found for education levels, smoking status, alcohol consumption and physical activity levels. For the plasma biomarkers, cases had higher levels of hemoglobin A1c (HbA1c), high-sensitivity C-reactive protein (hs-CRP), random glucose, random insulin, triglycerides (TG), and the ratio of TG to HDL-cholesterol (HDL-C), but lower HDL-C levels. The median (interquartile) concentration of adiponectin was 6.7 (5.2--8.3) µg/mL in men and 8.1 (6.4--10.5) µg/mL in women, and it was 6.7 (5.2--8.3) µg/mL in the cases and 8.4 (6.5--10.8) µg/mL in the controls.Table 1Baseline characteristics of cases and controls, case-control study nested within Singapore Chinese Health Study^a^.Cases (n = 571)Controls (n = 571)*P*-value^b^Age (years) at blood taken59.6 (6.1)59.7 (6.2)---Gender (Female)335 (58.7)335 (58.7)---Dialect (%)---Cantonese287 (50.3)287 (50.3)Hokkien284 (49.7)284 (49.7)Body mass index, kg/m^2^24.8 (3.6)22.8 (3.3)\<0.001Level of education (%)0.15No formal education104 (18.2)99 (17.3)Primary school255 (44.7)233 (40.8)Secondary and above212 (37.1)239 (41.9)History of Hypertension (%)265 (46.4)148 (25.9)\<0.001Cigarette smoking (%)0.08Never smokers410 (71.8)425 (74.4)Former smoker63 (11.0)71 (12.4)Current smokers98 (17.2)75 (13.1)Weekly moderate-to-vigorous activity (%)0.37\<0.5 hour/week456 (79.9)454 (79.5)0.5--3.9 hours/week82 (14.4)68 (11.9)≥4.0 hours/week33 (5.8)49 (8.6)Alcohol Intake (%)0.89Abstainers498 (87.2)497 (87.0)Weekly drinkers55 (9.6)59 (10.3)Daily drinkers18 (3.2)15 (2.6)Fasting status (yes)178 (31.2)156 (27.3)0.15Adiponectin, µg/mL6.7 (5.2--8.3)8.4 (6.5--10.8)\<0.001High-sensitivity C-reactive protein, mg/L1.8 (1.0--3.5)1.2 (0.6--2.3)\<0.001Random glucose, mmol/L6.0 (4.8--8.9)4.5 (4.1--5.3)\<0.001Random insulin, mIU/L14.7 (7.9--35.2)9.0 (4.5--22.0)\<0.001Total cholesterol, mmol/L5.31 (0.95)5.20 (0.85)0.05HDL cholesterol, mmol/L1.08 (0.24)1.23 (0.32)\<0.001Triglycerides, mmol/L2.2 (1.5--3.0)1.5 (1.1--2.2)\<0.001Ratio of triglycerides to HDL cholesterol1.3 (0.8--2.1)2.0 (1.3--3.0)\<0.001Hemoglobin A1c, %6.83 (1.44)5.55 (0.27)\<0.001Hemoglobin A1c, mmol/mol5138\<0.001^a^Data are expressed as mean (SD) for continuous variables with normal distribution, median (interquartile range) for continuous variables with skewed distribution, and n (percentage) for categorical variables. Cases and controls are matched on age at blood taken (±3 years), gender, dialect, and date of blood collection ( ± 6 months).^b^ *P*-values were based on conditional logistic regression.

Among the healthy control subjects, plasma adiponectin levels were inversely correlated with BMI, hs-CRP, random insulin, TG and the ratio of TG to HDL-C (Pearson's coefficient *r* = −0.15, −0.19, −0.20, −0.43, and −0.50, respectively; all *P* \< 0.001), and positively correlated with age and plasma HDL-C level (Pearson's coefficient *r* = 0.11, and 0.49, *P* \< 0.01) (Supplemental Table [S1](#MOESM1){ref-type="media"}).

The association between adiponectin and risk of T2D is presented in Table [2](#Tab2){ref-type="table"}. In the model with adjustment for T2D risk factors, higher plasma adiponectin levels were associated with a lower T2D risk, and the odds ratio (OR) and 95% confidence interval (CI) comparing the highest vs. lowest tertiles was 0.19 (0.12, 0.30; *P*-trend \< 0.001). The association was slightly attenuated after adjusting for hs-CRP, and the ratio of TG to HDL-C (OR 0.31; 95% CI: 0.20, 0.51; *P*-trend \< 0.001), and random glucose and insulin levels (OR 0.30; 95% CI: 0.17, 0.55; *P*-trend \< 0.001). Moreover, significant associations were found in 292 case-control pairs with the cases having baseline HbA1c \< 6.5% (48 mmol/mol) at the time of blood-taking, as well as in 279 case-control pairs with the cases having baseline HbA1c ≥6.5% (48 mmol/mol). In addition, the adiponectin-T2D association remained significant among 146 case-control pairs with HbA1c \< 6.0% (42 mmol/mol). Significant interaction was found with BMI status (*P* for interaction = 0.041; Supplemental Table [S2](#MOESM1){ref-type="media"}), and the association was stronger among overweight/obese subjects (BMI ≥23.0 kg/m^2^) than lean conterparts (BMI \< 23.0 kg/m^2^). No statistically significant interactions were found with other variables.Table 2Odds ratios (95% confidence intervals) for risk of type 2 diabetes according to tertiles of adiponectin, the Singapore Chinese Health Study.Tertiles of adiponectin concentrations*P* for trend^a^per 1 log µg/mLT1T2T3***Whole dataset***Median (range)5.5 (1.4, 7.1)8.3 (7.2, 9.8)11.8 (9.9, 29.9)Cases/controls328/191173/19170/189Model 1^b^1.000.55 (0.40, 0.76)0.19 (0.12, 0.30)\<0.0010.16 (0.10, 0.25)Model 2^c^1.000.67 (0.48, 0.95)0.31 (0.20, 0.51)\<0.0010.26 (0.16, 0.42)Model 3^d^1.000.80 (0.52, 1.23)0.30 (0.17, 0.55)\<0.0010.26 (0.14, 0.48)***Limited to cases with baseline hemoglobin A1c*** ≥ ***6.5% (48 mmol/mol) and their matched controls***Median (range)5.5 (1.4, 7.0)8.1 (7.1, 9.7)11.8 (9.8, 29.9)Cases/controls159/9888/9232/89Model 1^b^1.000.63 (0.41, 0.99)0.19 (0.10, 0.37)\<0.0010.13 (0.07, 0.25)Model 2^c^1.000.86 (0.53, 1.38)0.35 (0.17, 0.71)0.010.22 (0.11, 0.44)Model 3^d^1.002.08 (0.87, 4.98)0.27 (0.08, 0.90)0.200.26 (0.09, 0.82)***Limited to cases with baseline hemoglobin A1c*** \< ***6.5% (48 mmol/mol) and all the controls***Median (range)5.7 (2.1, 7.5)8.7 (7.6, 10.0)12.1 (10.1, 26.7)Cases/controls185/10171/9636/95Model 1^b^1.000.38 (0.23, 0.62)0.18 (0.09, 0.33)\<0.0010.18 (0.10, 0.34)Model 2^c^1.000.47 (0.28, 0.80)0.29 (0.15, 0.58)\<0.0010.32 (0.16, 0.63)Model 3^d^1.000.57 (0.32, 1.04)0.32 (0.14, 0.70)0.0030.32 (0.15, 0.70)***Limited to cases with baseline hemoglobin A1c*** \< ***6.0% (42 mmol/mol) and all the controls***Median (range)5.9 (2.2, 7.5)8.7 (7.6, 10.0)12.2 (10.1, 26.7)Cases/controls78/4947/5021/47Model 1^b^1.000.56 (0.29, 1.09)0.21 (0.09, 0.49)\<0.0010.25 (0.11, 0.56)Model 2^c^1.000.79 (0.38, 1.63)0.36 (0.14, 0.90)0.0370.44 (0.17, 1.10)Model 3^d^1.000.77 (0.34, 1.77)0.34 (0.12, 0.98)0.060.40 (0.14, 1.19)^a^Linear trend was tested by using the median level of each tertile of adiponectin.^b^Model 1: adjusted for age at blood taken (continuous), smoking (never, ever smoker), alcohol intake (never, ever drinker), weekly moderate-to-vigorous activity (\<0.5, ≥0.5 hours/week), education level (primary school and below, secondary or above), history of hypertension (yes, no), fasting status (yes, no), and body mass index (continuous);^c^Model 2: Model 1 plus adjusted for high-sensitivity C-reactive protein, and the ratio of triglycerides to high-density lipoprotein cholesterol (both in tertiles).^d^Model 3: Model 2 plus adjusted for random glucose and random insulin (both in tertiles).

The summary statistics for the predictive performance of adiponectin is presented in the Supplemental Tables [S3](#MOESM1){ref-type="media"} and [S4](#MOESM1){ref-type="media"}. The area under the receiver operating characteristic curve (AUC) for base model 1, which included education level, physical activity, history of hypertension, BMI, TG, HDL-C, and hs-CRP, was 0.74 (95% CI: 0.71, 0.77). Addition of adiponectin showed statistically significant improvement in AUC (AUC change = 0.02, *P* \< 0.05), reclassified 33% individuals more appropriately (net reclassification improvement \[NRI\] = 0.33, *P* \< 0.001) and led to an integrated discrimination improvement (IDI) of 0.03 (*P* \< 0.001). Base model 2, with additional inclusion of random glucose and insulin levels, had an AUC of 0.82 (95% CI: 0.80, 0.85). Adding adiponectin did not improve AUC significantly, but resulted in statistical significant NRI (0.19, *P* = 0.003) and IDI (0.01, *P* \< 0.001), indicating that the difference in average predicted risks between individuals with and without T2D increased significantly when adiponectin was included in the prediction model. Base model 3, substituting random glucose in base model 2 with HbA1c, had an AUC of 0.87 (95% CI: 0.84, 0.89), which was significantly higher than the AUC of base model 2 (AUC change = 0.05, *P* \< 0.001). Similar to base model 2, adding adiponectin to base model 3 did not improve AUC, but resulted in small yet marginally significant NRI (0.12, *P* = 0.051) and IDI (0.01, *P* \< 0.05).

Meta-analysis {#Sec4}
-------------

Our initial search identified 2159 potentially relevant citations (Supplemental Figure [S2](#MOESM1){ref-type="media"}). After screening for title, abstract and full texts, we included 33 prospective cohort studies based on 31 articles (2 articles reported results for 4 cohort studies), and the characteristics of the studies are shown in the Tables [3](#Tab3){ref-type="table"}--[4](#Tab4){ref-type="table"}. Eighteen studies included participants from Europe, 9 studies from North America, and 6 studies from Asia. There were 7504 T2D cases among 64,696 participants including our study. The duration of follow-ups varied from 1 to 18 years, the mean ages ranged from 26.5 to 74.8 years. Four studies were conducted in men only^[@CR19],[@CR23],[@CR32],[@CR38]^, and two studies were in women only^[@CR9],[@CR27]^, while 28 studies were in both sexes, among which five studies provided risk estimates for men and women separately^[@CR7],[@CR10],[@CR15],[@CR17],[@CR28]^. Furthermore, study qualities ranged from 5 to 9 (Table [3](#Tab3){ref-type="table"}).Table 3Baseline characteristics of the 33 prospective studies included in the meta-analysisReference, YearStudy name or source of participantsStudy locationStudy designFollow-up yearsMean baseline age or rangeFemale (%)Number of cases/non-casesAdiponectin assayAscertainment of type 2 diabetesStudy qualityLindsay *et al*.^[@CR57]^Gila River Indian CommunityUSANested case-control6.7326670/70ELISAOGTT7Daimon *et al*.^[@CR58]^Funagata studyJapanCohort5585818/819ELISAOGTT7Snehalatha *et al*.^[@CR59]^Indian Diabetes Prevention ProgramIndiaCohort1454225/66RIAOGTT5Choi *et al*.^[@CR60]^South-West SeoulKoreaCohort370NA25/294RIAOGTT6Kanaya *et al*.^[@CR61]^Health ABCUSACohort57453143/2213RIA(1) self-report; (2) medication intake; (3) OGTT8Koenig *et al*.^[@CR38]^MONICA AusburgGermanyCohort18540115/772ELISAconfirmed self-report6Nakashima *et al*.^[@CR62]^Hawaii-Los Angeles-Hiroshima StudyUSACohort5.461.358112/654ELISAOGTT7Snijder *et al*.^[@CR28]^The Hoorn StudyNetherlandsCohort6.46054118/1146Latex turbidimetric immunoassayOGTT8Wannamethee *et al*.^[@CR32]^British Regional Heart StudyUKCohort5690105/3462ELISAConfirmed self-report7Heidermann *et al*.^[@CR27]^Nurses' Health StudyUSANested case-control12561001038/1136ELISAConfirmed self-report7Ley *et al*.^[@CR63]^Sandy Lake Health and Diabetes Project cohortCanadaCohort10275886/406RIA(1) self-report; (2) medication intake; (3) OGTT8Mather *et al*.^[@CR31]^Diabetes Prevention ProgramUSACohort15168115/925Latex turbidimetric immunoassayOGTT5Tábak *et al*.^[@CR64]^Whitehall II StudyUKNested case-control11.5513155/85Bio-Plex Suspension assay(1) self-report; (2) medication intake; (3) OGTT8Salomaa *et al*.^[@CR6]^FINRISK97FinlandCohort10.84650417/7410ELISA(1) medication; (2) hospital record and death registry8Health 2000 cohortFinlandCohort7.15354179/4798ELISA(1) medication; (2) hospital record and death registry8Thorand *et al*.^[@CR7]^MONICA/KORAGermanyCase-cohort10.95349460/1474ELISAConfirmed self-report8Zhu *et al*.^[@CR8]^ARICUSACase-cohort945--6463550/540ELISA(1) Physician diagnosis; (2) medication use; (3) OGTT9Fagerberg *et al*.^[@CR9]^population-based cohort of 64-year-old womenSwedenCohort5.57010069/272ELISAOGTT9Hanley *et al*.^[@CR10]^IRAS Family StudyUSACohort5416182/1014RIA(1) OGTT; (2) medication use8Hivert *et al*.^[@CR11]^KORA S4/F4GermanyCohort8634993/794RIA(1) Physician diagnosis; (2) OGTT8Framingham Offspring StudyUSACohort6.56056109/1914ELISA(1) OGTT; (2) medication use8Montonen *et al*.^[@CR12]^EPIC-PotsdamGermanyCase-cohort75158613/1965ELISAConfirmed self-report7Kizer *et al*.^[@CR13]^Cardiovascular Health StudyUSACohort10.67563309/3493ELISA(1) use of medication; (2) OGTT8Li *et al*.^[@CR14]^local government workers from Aichi perfectureJapanCohort5.34723164/2844ELISA(1) OGTT; (2) self-report9Lilja *et al*.^[@CR15]^Västerbotten Intervention ProgramSwedenCase-referent175348640/1564double antibody RIAsOGTT9Marques-Vidal *et al*.^[@CR16]^The CoLaus StudySwitzerlandCohort5.55257208/3634ELISA(1) OGTT; (2) presence of oral hypoglycaemic; (3) insulin treatment9Kim *et al*.^[@CR17]^Seuol Metabolic Syndrome Research InitiativesKoreaCohort4.44620652/4433ELISA(1) OGTT; (2) 3 outpatient treatment; (3) hospitalization due to type 2 diabetes7Rubio-Martin *et al*.^[@CR18]^Pizarra cohort studySpainCohort5446552/417EIAOGTT8Sans *et al*.^[@CR19]^MONICA-CataloniaSpainCohort9.450085/799Luminex xMAP technology(1) OGTT; (2) self-report8Julia *et al*.^[@CR20]^SU.VI.MAX studyFranceNested case-control13515182/1263ELISA(1) OGTT; (2) medication9Lindberg *et al*.^[@CR21]^Patients with Myocardial infarctionDenmarkCohort5.7642638/628Immunoturbidimetric assayRegistry, validated using medical records7Yamamoto *et al*.^[@CR22]^Hitachi Health StudyJapanCohort35210214/4377Immunoturbidimetric assay(1) OGTT; (2) HbA1c ≥6.5%; (3) under diabetes treatment9Neville *et al*.^[@CR23]^PRIME studyIrelandCohort14.7550151/1688ELISAConfirmed self-report8Abbreviations: Health ABC, Health, Aging and Body Composition; MONICA, MONIotring of trends and determinants in CArdiovascular disease; KORA, Cooperative Health Research in the Region of Augsburg; ARIC, The Atherosclerosis Risk in Communities Study; IRAS, The insulin resistance atherosclerosis study; EPIC, The European Prospective Investigation into Cancer and Nutrition study; SU.VI.MAX, SUpplementation en VItamines et Mineraux AntioXydants; PRIME, The Prospective Epidemiological Study of Myocardial Infarction; RIA, radioimmunoassays; EIA, enzyme immunoassay. Table 4Results of the 33 prospective studies included in the meta-analysis.Reference, YearComparisonModelRR 95% CIAdjustment for covariatesLindsay *et al*.^[@CR57]^Per SD incrementMultivariable0.59 0.38, 0.91Age, waist circumference, fasting and 2-h glucose, fasting insulin. Matched for BMI, age and sexDaimon *et al*.^[@CR58]^Highest tertile (median, 13.9 μg/mL) vs lowest (4.7 μg/mL)Multivariable0.11 0.01, 0.96Age, sex, waist-hip ratio, 2-h glucose, TNF-~1~Snehalatha *et al*.^[@CR59]^Per 1 μg/mL incrementMultivariable0.87 0.79, 0.95HbA1cChoi *et al*.^[@CR60]^Highest tertile (median, 23.8 μg/mL) vs lowest (7.9 μg/mL)Multivariable0.31 0.14, 0.71BMIKanaya *et al*.^[@CR61]^per 1 log μg/mLMultivariable1.04 0.69, 1.56Age, sex, race, BMI, visceral fat, hypertension, leptin, PAI-1, fasting glucose and insulin, HDL-C, TGKoenig *et al*.^[@CR38]^Highest tertile (median, 10.6 μg/mL) vs lowest (3.8 μg/mL)Multivariable0.55 0.35, 0.89Age, BMI, smoking, alcohol intake, physical activity, hypertension, history of myocardial infarctionModel 20.81 0.50, 1.33Additional adjustment for HDL-CNakashima *et al*.^[@CR62]^Highest tertile (median, 17.4 μg/mL) vs lowest (5.4 μg/mL)Multivariable0.56 0.32, 0.99Age, sex, BMI, waist-hip ratio, HOMA-IR, glucose tolerance classificationSnijder *et al*.^[@CR28]^Highest quartile (median, 28.4 μg/mL in men, 24.8 μg/mL in women) vs lowest (8.1 μg/mL in men, 8.5 μg/mL in women)Multivariable0.43 0.19, 0.94Age, waist-hip ratio, smoking, performance of sports, leptinModel 20.72 0.36, 1.42Additional adjustment for fasting and 2-h glucoseModel 30.75 0.38, 1.51Additional adjustment for TGWannamethee *et al*.^[@CR32]^Highest tertile (median, 13.7 μg/mL) vs lowest (3.6 μg/mL)Multivariable0.40 0.23, 0.70Age, BMI, social class, physical activity, smoking, alcohol intake, history of coronary heart disease or stroke, statin use, blood pressure, treatment for hypertensionModel 20.59 0.33, 1.04Additional adjustment for HOMA-IRModel 30.67 0.38, 1.20Additional adjustment for HDL-C and CRPHeidermann *et al*.^[@CR27]^Highest quintile (median, 28.4 μg/mL) vs lowest (8.1 μg/mL)Multivariable0.17 0.12, 0.25Age, BMI, ethnicity, physical activity, smoking, family history of diabetes, hormone therapy, alcohol intake, dietary factors. Matched for age at blood draw ( ± 1 year), date of blood draw ( ± 3 months), fasting status, raceModel 20.16 0.10, 0.27Additional adjustment for hyperlipidemia, hypertension and CRPModel 30.26 0.13, 0.51Additional adjustment for fasting insulinLey *et al*.^[@CR63]^Per SD incrementMultivariable0.68 0.51, 0.90age, sex, waist circumference, TG, HDL-C, hypertension, IGTMather *et al*.^[@CR31]^Per SD incrementMultivariate0.77 0.66, 0.89age, sex, race/ethnicityModel 20.84 0.71, 0.98Additional adjustment for change in weight, change in adiponectin and baseline and change in insulinogenic index, 1/fasting insulinTábak *et al*.^[@CR64]^Per 1 μg/mL incrementMultivariable0.87 0.77, 0.97Age, sex, BMI, physical activity, family history of diabetes, employment grade. Matched for matched on sex, age (5-year groups), and BMI (5 kg/m^2^ groups)Model 20.89 0.79, 0.99Age, sex, BMI, TC, TG, blood pressureModel 30.89 0.79, 1.00Additional adjustment for CRPModel 40.94 0.82, 1.07Additional adjustment for fasting glucoseSalomaa *et al*.^[@CR6]^Per SD incrementMultivariable0.67 0.61, 0.80Sex, non-HDL-C, HDL-C, TG, BMI, systolic blood pressure, current smoking, blood glucose, history of cardiovascular disease event, use of antihypertensive medicationPer SD incrementMultivariable0.70 0.60, 0.90Sex, non-HDL-C, HDL-C, TG, BMI, systolic blood pressure, current smoking, blood glucose, history of cardiovascular disease event, use of antihypertensive medicationThorand *et al*.^[@CR7]^Highest tertile (median 13.3 μg/mL in men, 18.1 μg/mL in women) vs. lowest tertile (6.7 μg/mL in men, 9.9 μg/mL in women)Multivariable0.28 0.20, 0.39Age, sex, survey, BMI, smoking, alcohol consumption, physical activityModel 20.38 0.27, 0.53Additional adjustment for systolic blood pressure, TC/HDL-C, parental history of diabetes mellitus, CRP, interleukin-6, soluble ICAM-1 and soluble E-selection, and leptinZhu *et al*.^[@CR8]^Highest quartile (weighted median: 10.61 μg/mL) vs. lowest (weighted median: 3.48 μg/mL)Multivariable0.40 0.25, 0.64Age, sex, ethnicity, center, hypertension, and parental history of diabetes, BMI, waist-to-hip ratioModel 20.46 0.29, 0.74Additional adjustment for inflammation scoreModel 30.52 0.32, 0.85Additional adjustment for fasting insulinModel 40.82 0.48, 1.42Additional adjustment for fasting glucoseFagerberg *et al*.^[@CR9]^Highest tertile (18.28--40.78 μg/mL) vs lowest tertile (3.68--11.36 μg/mL)Multivariable0.22 0.07, 0.69HOMA-IR, AIR, smoking, IFG, IGTHanley *et al*.^[@CR10]^per SD incrementMultivariable0.67 0.46, 0.97Age, sex, ethnicity, smoking, BMIModel 20.64 0.43, 0.94Age, sex, ethnicity, smoking, HDL-CModel 30.69 0.49, 0.99Age, sex, ethnicity, smoking, HOMA-IRModel 40.81 0.56, 1.16Age, sex, ethnicity, smoking, S~1~Model 50.75 0.53, 1.06Age, sex, ethnicity, smoking, IFGHivert *et al*.^[@CR11]^per SD incrementMultivariable0.57 0.40, 0.81Age, sex, BMIModel 20.58 0.41, 0.84Additional adjustment for HOMA-IRper SD incrementMultivariable0.53 0.39, 0.74Age, sex, BMIModel 20.69 0.51, 0.96Additional adjustment for HOMA-IR, resistin, TNF-alphaMontonen *et al*.^[@CR12]^Highest quintile (median 9.7 μg/mL in men, 14.4 μg/mL in women) vs. lowest quintile (3.07 μg/mL in men, 4.74 μg/mL in women)Multivariable0.18 0.12, 0.28Age, sex, education, sport activity, cycling, occupational activity, smoking, alcohol intake, consumptions of red meat, whole grain bread and coffee, BMI, waist-circumferenceModel 20.26 0.16, 0.40Additional adjustment for GGT, HDL-C, hs-CRPModel 30.28 0.17, 0.44Additional adjustment for HbA1cKizer *et al*.^[@CR13]^Highest quartile (median 23.6 μg/mL) vs. lowest (median 7.2 μg/mL)Multivariable0.41 0.28, 0.61Age, sex, race, income, smoking, alcohol, eGFR, prevalent congestive heart failure, prevalent atrial fibrillation, prevalent CHD, beta-blocker use, health status, BMIModel 20.79 0.50, 1.23Additional adjustment for systolic blood pressure, HDL-C, TG, CRP, HOMA-IRLi *et al*.^[@CR14]^Highest quintile (median 13.9 μg/mL) vs. lowest quintile (median 4.3 μg/mL)Multivariable0.72 0.42, 1.25Age, sex, smoking, physical activity, alcohol consumption, family history of diabetes, BMIModel 20.85 0.48, 1.49Additional adjustment for CRP, fasting blood glucose, insulinLilja *et al*.^[@CR15]^Highest quartiles (≥12.1 μg/mL in men, ≥18.4 μg/mL in women) vs. lowest quartile (≤6.2 μg/mL in men, ≤9.2 μg/mL in women)Multivariable0.40 0.30, 0.54BMIModel 20.49 0.35, 0.70Additional adjustment for TC, hypertension, smoking, physical activity, university education, first-degree diabetes heredity, fasting and postload glucoseModel 30.55 0.38, 0.78Additional adjustment for HOMA-IRMarques-Vidal *et al*.^[@CR16]^Highest quartile (mean 17.3 μg/mL) vs. lowest quartile (mean 3.7 μg/mL)Multivariable0.41 0.26, 0.65Age, gender, BMIModel 20.64 0.40, 1.03Additional adjustment for diabetes risk score (age, family history of type 2 diabetes, height, waist circumference, resting heart rate, presence of hypertension, HDL-C, TG, fasting glucose and serum uric acid)Kim *et al*.^[@CR17]^Highest tertil (≥6.23 μg/mL in men, ≥9.47 μg/mL in women) vs. lowest tertile (\<3.90 μg/mL in men, \<6.01 μg/mL in women)Multivariable0.67 0.46, 0.96Age, sex, BMI, waist circumferencesModel 20.67 0.45, 1.00Additional adjustment for fasting serum glucoseRubio-Martin *et al*.^[@CR18]^Highest tertile (\>13.2 μg/mL) vs. lowest tertile (\<6.6 μg/mL)Multivariable0.24 0.07, 0.82Age, sex, obesity, CRPSans *et al*.^[@CR19]^Per 1 log increaseMultivariable0.22 0.08, 0.61Age, BMI, leptinModel 20.25 0.09, 0.70Age, BMI, insulin, years of schoolModel 30.24 0.08, 0.72Age, BMI, leptin, years of school, DBP, HDL-C, TGModel 40.47 0.16, 1.40Age, BMI, leptin, fasting glucose, years of school, DBP, HDL-C, TGJulia *et al*.^[@CR20]^Highest tertile vs. lowest tertileMultivariable0.56 0.27, 1.18Age, sex, supplementation group, family history of diabetes and BMI. Matched for sex, age, BMI and initial supplementation group.Model 20.71 0.33, 1.53Additional adjustment for baseline glycaemia, TC and TGLindberg *et al*.^[@CR21]^Highest quartile (\>10.35 μg/mL) vs. lowest quartile (≤5.13 μg/mL)Multivariable0.16 0.04, 0.66Age and sexModel 20.17 0.04, 0.75Additional adjustment for hypertension, hypercholesterolemia, current smoking, previous MI, BMI, blood glucoseModel 30.15 0.02, 0.90Additional adjustment for TC, HDL-C, LDL-C, TGYamamoto *et al*.^[@CR22]^Highest quartile (≥9.6 μg/mL) vs. lowest (\<5.2 μg/mL)Multivariable0.40 0.25, 0.64Age, sex, family history, smoking, alcohol drinking, physical activity, BMIModel 20.53 0.33, 0.86Additional adjustment for HOMA-IRModel 30.56 0.35, 0.91Age, sex, family history, smoking, alcohol drinking, physical activity, BMI, HbA1cModel 40.69 0.42, 1.13Additional adjustment for HOMA-IRNeville *et al*.^[@CR23]^Highest tertile (\>6.66 μg/mL) vs. lowest (\<3.77 μg/mL)Multivariable0.29 0.17, 0.52Age, BMI, waist/hip ratio, alcohol status, smoking status, measures of socioeconomic status (includes material conditions and deprivation score), physical activityModel 20.37 0.20, 0.67Additional adjustment for TC, HDL-C, TG, systolic blood pressure, on drug treatment for hypertension, CRPModel 30.54 0.29, 0.99Additional adjustment for HOMA-IRAbbreviations: OR, odds ratio; CI, confidence interval; TNF-~1~, the tumour necrosis factor 1; PAI-1, plasminogen activator inhibitor 1; TC, total cholesterol; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; TG/HDL-C, the ratio of TG to HDL-C; CRP, C-reactive protein; hs-CRP, high-sensitivity CRP; IGT, impaired glucose tolerance; IFG, impaired fasting glucose; GGT, gamma-glutamyltransferase; ICAM-1, intercellular adhesion molecule 1; S~1~, insulin sensitivity index; eGFR, the epidermal growth factor receptor; CHD, coronary heart disease; DBP, diastolic blood pressure; MI, myocardial infarction.

The pooled relative risk (RR) comparing the highest to lowest tertile of adiponectin concentrations was 0.53 (95% CI: 0.47, 0.61) using the random-effects model (Figure [1](#Fig1){ref-type="fig"}), and results were similar when using the fixed-effects model (RR 0.54; 95% CI: 0.50, 0.59). A moderate heterogeneity was observed (*I* ^2^ = 48.7%; *P* = 0.001), and the meta-regression analysis suggested evidence of effect modification by level of adjustment (*P* = 0.08) (data not shown). We further performed stratified analysis by level of adjustment, and the association was attenuated after further adjustment for glycaemia markers and/or insulin sensitivity markers, while additional adjustment for lipids and/or inflammatory markers did not materially change the association (Supplemental Table [S5](#MOESM1){ref-type="media"}). When stratifying by baseline participant characteristics, the inverse association was consistently observed among all subgroups (Supplemental Table [S5](#MOESM1){ref-type="media"}).Figure 1Adjusted relative risks of adiponectin levels with risk of type 2 diabetes in the updated meta-analysis. The summary estimates were obtained from the most fully-adjusted models of each study using a random-effects model. The data markers indicate the adjusted relative risks (RRs) comparing extreme tertiles of adiponectin levels. The size of the data markers indicates the weight of the study, which is the inverse variance of the effect estimate. The diamond data markers indicate the pooled RRs.

Twelve studies (14 data points because two studies reported results for men and women separately^[@CR10],[@CR28]^) provided data for dose-response meta-analysis (Supplemental Table [S6](#MOESM1){ref-type="media"}). Cubic spline regression model suggested a linear dose-response relationship (*P* = 0.33 for nonlinearity) (Figure [2](#Fig2){ref-type="fig"}). The RRs of T2D with per 5 µg/mL increment in adiponectin levels were 0.75 (95% CI: 0.73, 0.77) in the random-effects model. No significant publication bias was detected (*P* = 0.12 in the Egger's test).Figure 2The association between concentrations of adiponectin and type 2 diabetes in the updated meta-analysis. The *Solid line* represents point estimates of relative risk for the adiponectin-diabetes association, and the *dotted lines* represent the upper and lower bound of 95% CIs. Cubic spline analysis was used to examine the association between adiponectin concentrations (categorical) and risk of developing type 2 diabetes using the most fully-adjusted models from reported studies. *P* = 0.33 for nonlinearity in the cubic spline regression model.

Discussion {#Sec5}
==========

In this nested case-control study, we found a strong dose-dependent association between higher plasma adiponectin levels and lower T2D risk, which seemed to be independent of established T2D risk factors, including lipids, inflammatory biomarker (hs-CRP), random glucose and insulin. Moreover, the inverse association was significantly stronger among overweight/obese subjects than their lean counterparts. Furthermore, adiponectin significantly improved T2D risk reclassification in this population. In an updated meta-analysis which pooled data from 34 prospective studies including the current study, participants in the highest tertile had almost half the risk of developing T2D compared to those in the lowest tertile (RR 0.53; 95% CI: 0.47, 0.61), and the adiponectin-T2D association appeared to be linear.

A previous meta-analysis of 13 prospective studies (2623 incident T2D cases and 14,598 participants) reported an inverse association between adiponectin levels and T2D risk (RR 0.72 for per 1-log µg/mL increment in adiponectin levels) across different populations^[@CR5]^, but no study was done in Chinese population. In the current study, we not only observed the inverse association in a Chinese population after comprehensive adjustment, but also conducted an updated meta-analysis with a much larger sample size (7504 incident T2D cases and 64,696 participants), which provided strong evidence for the role of adiponectin in the pathogenesis of T2D across diverse populations, a consistent finding despite methodologic variations such as adiponectin assays, diagnostic criteria for T2D and follow-up durations.

Several lines of evidence have hypothesized that adiponectin may act against T2D development by lowering blood glucose through improving insulin sensitivity. Mechanistic studies have shown that adiponectin improves insulin sensitivity by stimulating glucose utilization and fatty acid oxidation in the skeletal muscle and liver through improving AMP-activated protein kinase^[@CR4]^. Animal studies have shown that adiponectin levels drop in parallel with reduced insulin sensitivity, before the increment in glycemic levels^[@CR3]^. A recent Mendelian randomization study in humans provided further evidence between increased adiponectin levels and improved insulin sensitivity using ADIPOQ SNPs as instruments^[@CR39]^. Additionally, we found in our current meta-analysis that the adiponectin-T2D association was substantially attenuated in studies that adjusted for insulin sensitivity and/or glycaemia markers compared to studies that did not adjust for either one of them, suggesting that the association was at least partially mediated through insulin and glucose pathways. Moreover, the stratified analysis from the current meta-analysis suggested that lower adiponectin levels may contribute to an increased T2D risk through pathways independent of other important T2D pathogenic mechanisms such as dyslipidemia and inflammation. Although adiponectin is an adipose-specific protein and its concentration reduces with increasing level of obesity^[@CR40]^, the current cohort study together with previous studies^[@CR10],[@CR11],[@CR22]^ have shown that adjustment for markers of obesity, such as BMI or CT-assessed abdominal fat area, did not materially change the association between adiponectin and T2D risk, suggesting that low adiponectin levels could be associated with higher T2D risk through pathways that may not be related to systemic or regional fat deposition.

Moreover, our study found stronger relation of adiponectin with T2D risk in overweight/obese people than their leaner counterparts. In line with our results, a 4-year follow-up study of elderly British men found stronger association among obese participants (BMI ≥30.0 kg/m^2^) than non-obese counterparts^[@CR32]^. Similarly, a Japanese cohort study reported stronger association in overweight/obese individuals (BMI ≥25.0 kg/m^2^) than in normal weight people^[@CR22]^. Some other studies also found that the association between adiponectin levels and T2D were stronger in participants with higher metabolic risk profile^[@CR11],[@CR17],[@CR41]^. A recent Mendelian randomization study in a Swedish population also observed a stronger causal relation between adiponectin and insulin sensitivity in participants with higher BMI^[@CR39]^. Although the underlying mechanism for the observed interaction with obesity is still unclear, the Mendelian randomization study hypothesized that the observed interaction with BMI may be due to the interaction between adiposity and the ADIPOQ SNPs, in which the transcription factors could have been regulated by the inflammatory mediators to stimulate the binding site and thus cause up-regulation of the related gene^[@CR39]^. However, given the multiple statistical tests for interaction conducted and that some studies did not observe significant interactions with BMI^[@CR13],[@CR27],[@CR30]^, our observed interaction with BMI should be interpreted with caution.

In the current study, adding adiponectin beyond traditional risk factors and glucose markers (random glucose or HbA1c) did not improve discrimination (assessed by AUC), but improved risk reclassification (assessed by NRI and IDI) for T2D. In consistent with our results, two cohort studies from Switzerland and Germany did not observe significant improvement in AUC when adding adiponectin alone to base models that included fasting glucose^[@CR16],[@CR34]^. In contrast, results from a cohort in Hong Kong and EPIC-Potsdam study have shown that adiponectin improved AUC significantly beyond glucose markers^[@CR26],[@CR37]^, and interestingly, in a previous study conducted in Finland, adiponectin improved AUC and NRI significantly in the primary cohort (FINRISK97) but not in the validation cohort (Health 2000)^[@CR6]^. In addition, a T2D score comprising adiponectin and other five biomarkers has shown better predictive utility (assessed by AUC) than HbA1c and fasting glucose in a Danish population^[@CR33]^, and the predictive utility of the score was further validated in two cohorts from Finland^[@CR35]^ and US^[@CR36]^ using AUC and NRI.

Our study has several strengths. First, we have adjusted for well-established T2D factors and used comprehensive statistical methods to explore the predictive utility of adiponectin. Moreover, compared to the previous meta-analysis^[@CR5]^, our updated meta-analysis included more prospective studies with a tripled sample size; we have also included results from models that have adjusted for a comprehensive panel of T2D biomarkers (lipids and markers of inflammation, glycaemia and insulin sensitivity) to examine their impact on the adiponectin-T2D association, and further performed stratified analysis by these factors to explore potential heterogeneity among subgroups. Furthermore, we have performed a dose-response meta-analysis among 12 studies, and observed a linear association between adiponectin and T2D. However, the current study has some limitations as well. First, we measured adiponectin levels only once and some measurement errors are inevitable. In addition, the height and weight were self-reported and residual confounding was possible. Hence, this could lead to non-differential misclassifications and result in an underestimation of the true effect size of adiponectin on T2D risk. Furthermore, information of more precise surrogates for insulin resistance (such as fasting insulin, HOMA-IR, and insulin sensitivity index) and glycaemia markers (such as fasting glucose) were not available in the study, thus, random insulin and glucose levels were used as covariates in our models. Moreover, incident T2D was obtained from self-reported information, thus undiagnosed T2D may exist. However, we have used HbA1c as a selection criterion (\<6.0%) for controls to minimize bias due to undiagnosed T2D. In addition, we also conducted sensitivity analysis restricting to cases with HbA1c \<6.5% and \<6.0% at the time of blood collection and their respective controls, and observed similar adiponectin-T2D association. Furthermore, the present study was conducted in a middle-aged and elderly population with a higher T2D incidence and adiponectin levels, and the findings may not be applicable to younger age group^[@CR28]^. However, in the current meta-analysis, we did not observe any heterogeneity of results by age group, suggesting the finding will be most likely to be observed in younger people as well.

Materials and Methods {#Sec6}
=====================

Study population {#Sec7}
----------------

The design of the SCHS was described in detail previously^[@CR42]^. Briefly, the SCHS was established between 1993 and 1998, and recruited 63,257 Chinese adults aged 45--74 years. At recruitment, an in-person interview was conducted using a structured questionnaire to collect information of diet, lifestyle habits and medical history. Follow-up I interviews were conducted via telephone between 1999 and 2004 to update selected lifestyle habit and medical history. A total of 52,322 participants were re-contacted successfully, and among them, a total of 32,535 participants donated their bio-specimens during follow-up I visits. Follow-up II interviews were conducted via telephone from 2006 to 2010, and 39,528 participants were re-contacted successfully. Among the 32,535 participants who donated bio-specimens, 25,477 (78.3%) were re-contacted for follow-up II interviews. The study protocol was approved by the Institutional Review Boards at the National University of Singapore and the University of Pittsburgh, and all methods were performed in accordance with the relevant guidelines and regulations. Informed consent was provided with completion of the baseline interview.

Ascertainment of diabetes and other covariates {#Sec8}
----------------------------------------------

History of physician-diagnosed diabetes was asked at baseline and both follow-up interviews using the question: "Have you been told by a doctor that you have diabetes?" If the answer was "yes", participants were also asked for the age at which they were first diagnosed. The robustness and accuracy of the self-reported diabetes data has been confirmed in a validation study: among 1651 cohort participants who reported history of diabetes either at baseline or follow-up I interview, 98.9% were confirmed by medical records or telephone interview. Some participants (n = 619) refused or were not available for the validation study, but their main characteristics (age, sex, BMI etc.) were similar to those in the validation study^[@CR43]^.

Body weight and height were self-reported at baseline and both follow-ups. BMI is calculated as weight (kilograms) divided by height (meters) squared. For those with missing weight or height, BMI was calculated using imputed weight or height derived from the linear regression equation: Weight = y-intercept + gradient × height, where values for the y-intercept and gradient were derived from gender-specific weight-height regression lines obtained from all cohort participants with known heights and weights.

Establishment of nested case-control study {#Sec9}
------------------------------------------

For the current analysis, we established a nested case-control study of 571 cases and 571 matched controls within this cohort. All cases and controls were free of physician-diagnosed T2D, cardiovascular disease and cancer at baseline interview as well as the time of blood collection during 1999 and 2004. Cases were a total of 571 participants who subsequently reported to be diagnosed with incident T2D during follow-up II visit (2006--2010). Controls were chosen from the remaining participants who did not develop T2D or cardiovascular disease at follow-up II, and were matched for age (±3 years), date (±6 months) of blood collection, sex and dialect group with the cases on a 1:1 ratio. Furthermore, the selected controls were screened for the presence of undiagnosed T2D at the time of blood donation by HbA1c measurements. All matched controls with HbA1c ≥6.0% (42 mmol/mol) were considered ineligible for the study and a replacement control with the same matching criteria was randomly chosen among the remaining eligible subjects.

Laboratory procedures {#Sec10}
---------------------

Random morning peripheral blood samples were obtained, and frozen plasma aliquots from the cases and controls were analyzed simultaneously in the same batch at the National University Hospital Reference Laboratory, Singapore. Adiponectin levels were measured by ELISA/Evolis (Bio-Rad Laboratories, Hercules, CA). The within-assay and between-assay coefficients of variation were 3.9--5.9% and 6.3--7.0%, respectively. Plasma hs-CRP levels and blood lipids (total cholesterol, TG and HDL-C) were measured via colorimetric method on a chemistry analyzer (AU5800 Analyzer, Beckman Coulter, Brea, CA). HbA1c was measured by HPLC method using Bio-Rad Variant II™ System (Bio-Rad Laboratories, Hercules, CA) in red blood cells.

Statistical analysis {#Sec11}
--------------------

Study participants were divided into tertiles and the lowest tertile served as the reference group. We used conditional logistic regression models to compute the OR and corresponding 95% CI between adiponectin and T2D with adjustment for age (continuous), education level (primary school and below, secondary or above), smoking status (never, ever smoker), alcohol consumption (never, ever drinker), weekly moderate-to-vigorous physical activity levels (\<0.5, ≥0.5 hours/week), history of hypertension (yes, no), BMI (continuous), and tertiles of biomarkers, including the ratio of TG to HDL-C, hs-CRP, random glucose and random insulin levels. We also calculated the T2D risk associated with per one log mg/L increment in adiponectin levels, in order to compare with previous studies^[@CR5]^. To examine the impact of potential selection bias, we examined the adiponectin-T2D association among cases with HbA1c \<6.5% or \<6.0% and their matched controls. We stratified the analysis by sex, BMI, physical activity, smoking habits and hs-CRP level using unconditional logistical regression models with additional adjustment for sex and dialect group, and we used restricted cubic spline regression with 3 knots at 25^th^, 50^th^ and 75^th^ percentiles of adiponectin concentrations to examine the linearity of adiponectin-T2D association.

The predictive utility of adiponectin was examined by establishing three logistic regression models. Base model 1 included education level, physical activity, history of hypertension, BMI, TG, HDL-C, and hs-CRP; base model 2 additionally included random glucose and insulin. Since previous studies have shown that HbA1c levels outperform glucose levels in predicting T2D^[@CR44],[@CR45]^, we further established base model 3 to substitute random glucose from base model 2 with HbA1c levels. The improvement in discrimination was examined by comparing AUC between each base model and the model plus plasma adiponectin levels^[@CR46]^. Moreover, due to the limitation of AUC such as its insensitivity to model improvement^[@CR47]^, we also evaluated the category-free NRI and IDI^[@CR48]^. The goodness-of-fit of all models were assessed by Akaike information criteria (AIC), where lower AICs indicate better model fit.

Meta-analysis {#Sec12}
-------------

We performed an updated systematic review and meta-analysis of studies evaluating the association between adiponectin and T2D in adult populations since the date of the previous meta-analysis^[@CR5]^. We followed the guidelines in Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Meta-analysis of Observational Studies in Epidemiology^[@CR49]^. We searched systematically on PubMed for prospective human studies (including cohort, case-cohort, and nested case-control studies) assessing adiponectin-T2D associations between April 10, 2009 (the last date of literature research in the previous meta-analysis^[@CR5]^) up to September 10, 2016. Our searches included both MeSH terms and key words without restrictions on language (Supplemental Material).

Studies were excluded if they were: (1) irrelevant (not using adiponectin as the exposure or T2D as the outcome); (2) review, editorial, commentary, meta-analysis, animal or experimental study; (3) not prospective study (case-control, cross-sectional, and genetic studies). Identified studies were screened for titles and abstracts first, and then potentially relevant articles were reviewed for full-text (Supplementary Figure [S2](#MOESM1){ref-type="media"}). Studies included in the previous meta-analysis^[@CR5]^ were also reviewed for full-text and added into the current meta-analysis. Data extraction was conducted independently by 2 authors (Y.W., R.M.). Extracted information included study characteristics (title, authors, publication year, study name, study design, follow-up length), participant characteristics (location, ethnic origin, sample size, number of incident T2D cases, gender composition, mean age or age range), adiponectin assay, T2D assessment, and analysis strategy (statistical models and covariates controlled). In case of multiple studies involving the same cohort, the most updated or relevant study was selected. We extracted relative risk estimates from the most fully-adjusted multivariable models. Studies qualities were assessed by the Newcastle-Ottawa Quality Assessment Scale^[@CR50]^.

For the meta-analysis, RRs were used as the common measure of association, and ORs or hazard ratios (HRs) were considered as equivalent to RRs because of the low incident rate in most studies. To enhance consistency and improve comparability between studies, we transformed the originally reported RRs (per unit, per SD, per log increment, quartiles or quintiles) to a uniform comparison involving extreme tertiles of adiponectin levels using standard statistical methods which were described previously^[@CR51],[@CR52]^. When RRs were reported in subgroups rather than the total sample in a study, a within-study RR was attained first using a fixed-effect analysis. RRs and corresponding 95% CIs were pooled by the DerSimonian-Laird random-effects models^[@CR53]^, and fixed-effect models were used in sensitivity analyses. Between-study heterogeneity was evaluated by Cochran χ^2^ and *I* ^*2*^ Statistic^[@CR54]^. Meta-regression analyses were used to examine the influence of certain factors on observed associations, including location, ethnicity, age, sex, follow-up duration, number of T2D cases, adiponectin assay, ascertainment of T2D, level of adjustment, and study quality. Stratified analyses were performed to evaluate the influences of baseline participant characteristics on the results. Potential for publication bias was examined by Egger's test^[@CR55]^. To detect any nonlinear association, restricted cubic spline regression model with three knots at 25%, 50% and 75% percentiles adiponectin distribution was applied. When the nonlinear hypothesis was rejected, a two-stage, log-linear, dose-response regression function was then used for both the fixed-effect and random-effect models to estimate the risk of T2D per 5 µg/mL increment in adiponectin levels^[@CR56]^. Studies which reported case number, total number of participants, as well as adiponectin median value in each category were included in the dose-response meta-analysis. All *P* values were two-sided, and data were analyzed with STATA version 14 (Stata Corp, College Station, Texas).

Data availability {#Sec13}
-----------------

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Conclusion {#Sec14}
==========

In conclusion, the strong, dose-dependent association between increased adiponectin levels and decreased T2D risk has been demonstrated in a Chinese population, and adiponectin may be a useful marker for T2D prediction among Chinese. Our meta-analysis strengthens the evidence that adiponectin is involved in T2D pathogenesis, and further clinical studies are needed to investigate the feasibility of targeting adiponectin through pharmacological, dietary and physical activity interventions to reduce the risk of T2D in high-risk population.
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